Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO

According to the World Health Organization (WHO), anemia is defined as hemoglobin (Hb)  levels <12.0 g/dl in women and <13.0 g/dl in men . Anemia affects around 33% of the world’s population, and about half the cases are due to iron  deficiency. Preschool age children, women of child-bearing age, and pregnant women are  particularly at risk. Iron Deficiency anemia is the commonest cause of anemia in every  country of the world. Iron Deficiency Anemia (IDA) significantly impacts an individual’s  Quality of Life (QOL) concerning health, productivity, and socioeconomic well-being. Anemia results in a loss of up to 4.5% of GDP per annum in developing countries, equating  to 1.18% of India’s GDP.[38] Age-standardized Years Lived with Disability (YLDs) due to  anemia are higher in women than in men across socio-demographic indices. The management of this disorder involves dietary and drug supplementation with various  forms of iron. Despite the availability of iron supplements, anemia remains a global health  challenge. Also, there are many limitations of oral iron supplements, with the most common  being the frequency and severity of side effects. In contrast, Unani medicine, known for being safe, effective, readily accessible, cost-efficient, and with least adverse effects, can play a pivotal role in addressing this issue through research. The Unani system employs a holistic approach, with most anemia treatments combining iron  and hepatoprotective/hemopoietic agents. The purpose of this study is to evaluate the efficacy and safety of the combination therapy of  Qurs kushta e khabsul hadeed and sharbat-e-Anar Shirin in the treatment of IDA and to  compare the safety and efficacy data of the above-mentioned combined therapy in the  treatment of IDA on modern scientific parameters.